SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a - 16 OR 15d - 16 OF
THE SECURITIES EXCHANGE ACT OF 1934
For the month of March, 2007
SkyePharma PLC
SkyePharma PLC, 105 Piccadilly, London W1J 7NJ England
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40F.
Form 20-F X Form 40-F
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes No X
If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- _______
For immediate release 12 March 2007
SkyePharma PLC (the "Company")
HOLDING IN COMPANY
On 9 March 2007, the Company received notification by Aviva plc of a disclosure
of a notifiable interest, following the implementation of the Transparency
Directive, of 43,183,326 ordinary shares of 10p each representing 5.73% of the
issued share capital in the Company.
The notifiable interest comprises 41,335,090 ordinary shares, representing 5.48%
being a direct holding and 1,848,236 ordinary shares, representing 0.25%, being
held indirectly.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
SkyePharma PLC
By: /s/ John Murphy
Name: John Murphy
Title:
Company Secretary
Date: March 12, 2007